Federal health researchers are challenging the Trump administration’s decision to terminate multiple grants focused on racial health disparities and Alzheimer's disease risk in Black communities. The National Institutes of Health (NIH) halted these projects, citing grounds that the studies were "not science" and fell under the category of diversity, equity, and inclusion (DEI) initiatives rather than rigorous biomedical research. The terminations have disrupted long-term data collection, stranded millions of dollars in taxpayer-funded research, and raised ethical concerns about the treatment of study participants who contributed personal health data expecting answers.
In Pittsburgh, a five-year study examining why Black Americans are twice as likely as their white peers to develop Alzheimer's disease was cut short in its final year, after more than $8 million in taxpayer money had already been spent. Similarly, a $2.9 million project at Emory University in Atlanta investigating how daily experiences of racial discrimination affect the brain and body was terminated in July. These actions are part of a broader federal effort to defund grants containing keywords such as "disparities," "minority," and "racial," leading to a wave of lawsuits against the Department of Health and Human Services (HHS) and the NIH.
What the Right Is Saying
The Trump administration and HHS officials maintain that the defunded grants failed to meet rigorous scientific standards and did not translate into better health outcomes. A spokesperson for HHS stated, "Massive amounts of DEI grants have failed to translate into better health outcomes for minority populations." The administration asserts that these funds are being redirected toward research that will help all Americans, including minority populations, live longer and healthier lives.
Officials argue that the NIH is shifting money into "rigorous research" in line with President Trump's directives. The administration contends that projects labeled with terms like "disparities" or "racial" often prioritize social narrative over biomedical efficacy. By terminating these grants, the administration aims to ensure that federal resources are allocated to studies that produce measurable, actionable health results rather than those deemed subjective or political in nature.
What the Left Is Saying
Researchers and community advocates argue that the terminations represent a political interference in scientific peer review and a breach of trust with marginalized communities. La'Vette Wagner, the field coordinator for the Pittsburgh study, stated that the grant was not a "DEI study" but "something that was happening that was real." She noted that the study had successfully challenged misconceptions about memory loss in the Hill and Homewood neighborhoods, with families beginning to distinguish between normal aging and dementia.
Negar Fani, a neuropsychologist at Emory University whose project was terminated, argued that her work was "simply brain science research." She expressed concern for the participants who feel abandoned, stating, "It takes a lot to restore trust with the Black community, who has experienced so many different betrayals." Jill Rosenthal, director of public health policy at the Center for American Progress, characterized the decisions as "unprecedented" and driven by "political biases" rather than evidence-based processes. Rosenthal stated, "We're wasting resources, we're wasting the opportunity to identify cures for diseases."
Study participants like Roderick Blair, 70, expressed frustration that their contributions yielded no results. "The community will look like, 'Oh, they came in here, they took all our stuff, they checked us out. Now they're gonna leave us hanging,'" Blair said. Ann Cohen, director of Pittsburgh's Alzheimer's Disease Research Center, highlighted the ethical dilemma of retaining biological samples from participants whose studies were abruptly halted, noting, "You lose trust a hell of a lot faster than you build it."
What the Numbers Show
According to a report by the Association of American Medical Colleges, the NIH awarded 2,000 fewer grants for multiyear studies in 2026 compared to 2025, representing a total reduction of $200 million in funding. The Pittsburgh Alzheimer's study had spent over $8 million before being halted in its fifth year. The Emory University project, which was terminated two years into a five-year term, had a total budget of $2.9 million, leaving approximately $2.3 million needed to complete the research. Another halted study in Pittsburgh, led by Ann Cohen, had spent $5.2 million over three years.
Data from the Alzheimer's Association indicates that 55% of Black Americans believe significant memory loss is a natural part of aging rather than a disease, a misconception the Pittsburgh study was addressing. Black Americans are twice as likely as white Americans to develop Alzheimer's disease. The Emory study had enrolled 66 of its 220 target participants before termination.
The Bottom Line
The termination of these grants has created a legal and ethical vacuum for researchers and participants. Scientists like Andrea Rosso and Ann Cohen have joined lawsuits against the NIH and HHS, arguing that the cancellations violate scientific peer review processes. For the communities involved, the immediate impact is the loss of potential health insights and the erosion of trust in federal health institutions. Researchers are now tasked with managing the aftermath: securing remaining funds, deciding the fate of collected biological data, and attempting to communicate outcomes—or the lack thereof—to participants who have been engaged in these studies for years.
Legal challenges are expected to continue as the administration proceeds with its review of grants containing specific keywords. The outcome of these lawsuits may determine whether the funding is reinstated or if the projects are permanently dissolved, further influencing the trajectory of health disparity research in the United States.